Cagrilintide for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Cagrilintide is an experimental, unapproved drug, injected once weekly, that copies amylin, a meal-ending hormone from the pancreas, to control weight. On its own it produces meaningful, well-replicated weight loss in adults with excess weight; smaller effects on blood pressure and, in diabetes, blood sugar are reasonably supported. Side effects are mostly stomach-related. Evidence is short-term and almost entirely company-funded; no study has tested whether it extends healthy life. (Full Review)

Protocol

Standard trial dose
2.4 mg once weekly
Subcutaneous injection; the dose used in phase 3 trials
Titration schedules
4-week steps
0.25, 0.5, 1.0, 1.7, then 2.4 mg
Time of day
Same weekday each week
Any time, with or without food; evening injection may let early nausea pass during sleep
Time to effect
Weight loss
During titration
Begins within the 16-week titration; continued through 68 weeks in phase 3
Blood pressure
By 68 weeks
Lower than placebo in REDEFINE 1
Blood sugar in type 2 diabetes
32–68 weeks
Fall seen at 32 weeks; lower than placebo at 68 weeks

Benefits

Contraindications
  • Pregnancy, planned pregnancy or breastfeeding
  • Confirmed gastroparesis
  • Hypoglycemia unawareness on insulin
  • Underweight (BMI under 18.5) or history of anorexia nervosa or bulimia
  • Under 18 years
Key Interactions
  • Semaglutide: doubled gastrointestinal adverse events
  • Antihypertensives (lisinopril, amlodipine): additive blood pressure lowering
Theoretical (inferred from mechanism)
  • QT-prolonging drugs (moxifloxacin, citalopram): added heart-rhythm risk not expected
  • Insulin and sulfonylureas (glipizide, glimepiride): hypoglycemia
  • Oral drugs needing rapid onset (acetaminophen, oral contraceptives): delayed or blunted absorption
  • Narrow-range oral drugs (warfarin, levothyroxine): altered absorption
  • Gut-slowing drugs (opioids, loperamide): additive constipation and delayed emptying
  • Glucose-lowering supplements (berberine, chromium): additive glucose lowering, mainly relevant with insulin or sulfonylureas
  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium): additive blood pressure lowering
  • Fiber appetite supplements (glucomannan, psyllium): additive fullness and slowed emptying
  • Alcohol: additive hypoglycemia risk with insulin and dehydration risk with vomiting

Risk & Side Effects

  • High: Gastrointestinal adverse events
  • Medium: Injection-site reactions; fatigue; dizziness
  • Low: Serious adverse events; gallbladder events; hypoglycemia with insulin or other glucose-lowering drugs; cancer signal from calcitonin receptor activation
  • Speculative: Aspiration risk during anesthesia; muscle and bone loss during weight loss

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track percentage change from own baseline Main expected effect
Blood pressure Below 120/80 mm Hg Expected to change; safety check for low pressure
HbA1c 4.0–5.6% Expected to change in diabetes or prediabetes
Fasting glucose 70–99 mg/dL Safety check for hypoglycemia with insulin or sulfonylureas
eGFR 60 mL/min/1.73 m² or higher Safety check for dehydration from vomiting or diarrhea
Lean mass by DXA No established target; track change from own baseline Safety check for muscle loss

Cadence: Baseline before starting; at 4, 8, 12 and 16 weeks during titration, then every 3 months for the first year and every 6–12 months thereafter. Weight and blood pressure weekly at home during titration. HbA1c and kidney function every 3 months with diabetes, otherwise every 6–12 months. Repeat body-composition scan after 6–12 months.

Qualitative Assessment

  • Appetite and fullness after meals
  • Frequency and severity of nausea, constipation or diarrhea
  • Energy levels and fatigue
  • Dizziness on standing
  • Injection-site redness or itching
  • Strength and exercise capacity